U.S. Medical Equipment Stock News

As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...

The board of Dime Community Bancshares, Inc. ( NASDAQ:DCOM ) has announced that it will pay a dividend of $0.25 per...

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

Despite an already strong run, Huntington Ingalls Industries, Inc. ( NYSE:HII ) shares have been powering on, with a...

Agilysys (NASDAQ:AGYS) has had a rough month with its share price down 7.8%. But if you pay close attention, you might...

Novavax, Inc. ( NASDAQ:NVAX ) shareholders are no doubt pleased to see that the share price has bounced 32% in the last...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Despite the fact that Kelly Services, Inc. (NASDAQ:KELY.A) stock rose 13% last week, insiders who sold US$722k worth of...

Some LSB Industries, Inc. ( NYSE:LXU ) shareholders may be a little concerned to see that the Independent Director...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

ClearOne, Inc. ( NASDAQ:CLRO ) shareholders would be excited to see that the share price has had a great month, posting...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

TTM Technologies, Inc. ( NASDAQ:TTMI ) shares have continued their recent momentum with a 29% gain in the last month...

Kopin Corporation ( NASDAQ:KOPN ) is possibly approaching a major achievement in its business, so we would like to...

Shareholders in Amphenol Corporation ( NYSE:APH ) may be thrilled to learn that the analysts have just delivered a...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Amdocs fair value estimate is US$130 Amdocs is estimated to be...

Arcturus Therapeutics Holdings Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at the Westin St. Francis Hotel in San Francisco, with Founder, President, CEO and Director Joseph E. Payne speaking. This high-profile conference appearance offered Arcturus a platform to showcase its pipeline and corporate story to a concentrated audience of healthcare-focused investors and industry peers. With this conference spotlight and recent share price...

Honat Bancorp (HONT) has put another solid quarter on the board, with Q2 2025 revenue of US$11.4 million and basic EPS of US$2.57 feeding into trailing twelve month EPS of US$10.46 on revenue of US$44.6 million and net income of US$15.0 million. Over the past year, the company has seen revenue move from US$38.8 million to US$44.6 million on a trailing basis, while EPS climbed from US$8.33 to US$10.46, and earnings growth of 19% has supported a net profit margin of 33.5% compared with 31.2% a...

If you are wondering whether CareDx at around US$20.19 is starting to look interesting again, you are not alone. This article is here to help you think through the value question. The share price has seen a 7.3% gain over the last week, while the 30 day return sits at a 1.8% decline and the 1 year return is a 8.4% decline. This is against a 42.3% gain over 3 years and a 78.4% decline over 5 years. Recent news coverage of CareDx has focused on how investors are reassessing the company in...

3D Systems recently presented at the 28th Annual Needham Growth Conference while highlighting expanded Aerospace & Defense operations, new FDA clearance for its VSP Orthopedics platform, and balance-sheet strengthening through equity-funded debt reduction. Together, the push into defense-focused manufacturing, broader orthopedic indications, and efforts to reinforce the capital structure underscore how the company is repositioning around mission-critical, higher-value applications. We’ll now...

Autolus Therapeutics recently reported preliminary unaudited 2025 net product revenue of about US$75 million and issued 2026 guidance of US$120 million to US$135 million, alongside progressing obe-cel into Phase 2 trials for lupus nephritis and other indications. The company also secured UK and EU approvals for AUCATZYL®, pairing early commercial traction with expanding clinical data in both pediatric oncology and autoimmune disease. Next, we’ll examine how this combination of higher revenue...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

As the U.S. market navigates a landscape marked by fluctuating indices and inflation data that aligns with expectations, investors are keenly assessing the implications for high-growth sectors like technology. In this environment, identifying promising tech stocks involves evaluating companies that demonstrate resilience amidst economic shifts and possess innovative capabilities to capitalize on emerging opportunities.